Literature DB >> 2154105

Oral itraconazole and topical miconazole with débridement for Acanthamoeba keratitis.

Y Ishibashi1, Y Matsumoto, T Kabata, R Watanabe, S Hommura, K Yasuraoka, K Ishii.   

Abstract

We treated three patients who had Acanthamoeba keratitis with oral itraconazole, a new antifungal agent, topical miconazole, and surgical débridement of the lesion. In these patients, healing and regression of the keratitis began six or seven days after initiation of oral itraconazole and miconazole 0.1% eyedrops (every hour during the day). The clinical signs of corneal infection disappeared after nine weeks in Patient 1, after five weeks in Patient 2, and after eight weeks in Patient 3. Visual acuities improved markedly from hand motions to 20/30 in Patient 1, from counting fingers to 20/16 in Patient 2, and from hand motions to 20/40 in Patient 3. In these patients, no systemic or topical signs of toxicity or adverse reactions were noted during the course of treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2154105     DOI: 10.1016/s0002-9394(14)75974-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  17 in total

1.  Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy.

Authors:  Elmer Y Tu; Charlotte E Joslin; Megan E Shoff
Journal:  Cornea       Date:  2010-09       Impact factor: 2.651

Review 2.  Therapeutic dilemmas in external ocular diseases.

Authors:  P A Asbell; M A Torres
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

3.  Screening of the in vitro amoebicidal activities of Pastinaca armenea (Fisch. & C.A.Mey.) and Inula oculus-christi (L.) on Acanthamoeba castellanii cysts and trophozoites.

Authors:  Serpil Degerli; Seyda Berk; Erdogan Malatyali; Bektas Tepe
Journal:  Parasitol Res       Date:  2011-07-07       Impact factor: 2.289

Review 4.  The Development of Drugs against Acanthamoeba Infections.

Authors:  Ruqaiyyah Siddiqui; Yousuf Aqeel; Naveed Ahmed Khan
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba isolates.

Authors:  Simon Kilvington; Reanne Hughes; James Byas; John Dart
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Silver nanoparticle conjugation affects antiacanthamoebic activities of amphotericin B, nystatin, and fluconazole.

Authors:  Ayaz Anwar; Ruqaiyyah Siddiqui; Muhammad Asim Hussain; Dania Ahmed; Muhammad Raza Shah; Naveed Ahmed Khan
Journal:  Parasitol Res       Date:  2017-12-07       Impact factor: 2.289

Review 7.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

8.  Acanthamoeba-specific human T-cell clones isolated from healthy individuals.

Authors:  Y Tanaka; S Suguri; M Harada; T Hayabara; K Suzumori; N Ohta
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

9.  In vitro effectiveness of Thymus sipyleus subsp. sipyleus var. sipyleus on Acanthamoeba castellanii and its cytotoxic potential on corneal cells.

Authors:  Zubeyde Akin Polat; Bektas Tepe; Ayse Vural
Journal:  Parasitol Res       Date:  2007-07-30       Impact factor: 2.289

10.  Amoebicidal efficiencies of various diamidines against two strains of Acanthamoeba polyphaga.

Authors:  D Perrine; J P Chenu; P Georges; J C Lancelot; C Saturnino; M Robba
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.